Rogers (ROG) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
18 Feb, 2026Executive summary
Q4 2025 sales reached $202 million, near the high end of guidance, with adjusted EPS of $0.89 and adjusted EBITDA margin of 17.1%, both exceeding guidance and up 5% and 94% year-over-year, respectively.
Year-over-year, Q4 sales grew 5% and adjusted EBITDA margin improved by 500 basis points, driven by end market recovery, cost savings, and structural changes.
Net sales for 2025 were $810.8 million, with gross margin at 31.7% for the year and 31.5% in Q4.
Significant free cash flow was generated, with $14 million in Q4 share repurchases and a leaner cost structure positioning for 2026.
Structural changes included a more agile organization, enhanced customer relationships, and faster R&D execution.
Financial highlights
Q4 adjusted EBITDA was $34.4 million, up from $23.3 million in Q4 2024; margin improved to 17.1%.
Adjusted EPS nearly doubled year-over-year to $0.89, reflecting higher sales and lower operating expenses.
Cash at year-end was $197 million, up $29.2 million from Q3, with $46.9 million provided by operations in Q4.
Free cash flow for Q4 2025 was $42.2 million, with $71.1 million for the full year.
Full-year capital expenditures were $50 million, at the low end of guidance.
Outlook and guidance
Q1 2026 sales are expected between $193 million and $208 million, a midpoint increase of 5% year-over-year.
Q1 gross margin guidance is 30.5%-32.5%, with adjusted EBITDA margin at 15.5% (midpoint), up 530 basis points year-over-year.
Adjusted EPS for Q1 2026 is forecasted at $0.45-$0.85, with a midpoint of $0.65 versus $0.27 in Q1 2025.
Full-year 2026 capital expenditures are guided at $30-$40 million.
Focus areas for 2026 include leveraging capacity, securing design wins, maintaining cost discipline, and increasing adjusted EBITDA.
Latest events from Rogers
- Q4 results met guidance; cost controls and innovation support H2 2025 recovery plans.ROG
Q4 20243 Feb 2026 - Gross margin and adjusted EPS improved in Q2, with EMS growth offsetting AES softness.ROG
Q2 20242 Feb 2026 - Strong growth in EV and high-tech markets, with margin expansion and global innovation focus.ROG
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Earnings beat guidance, but sales fell on weak EV/HEV demand; Q4 outlook remains cautious.ROG
Q3 202418 Jan 2026 - Q1 2025 sales fell but cash rose; Q2 guidance stable despite ongoing tariff risks.ROG
Q1 202527 Dec 2025 - Operational improvements and innovation in high-growth markets drive optimism for H2 recovery.ROG
Gabelli Funds' 16th Annual Specialty Chemicals Symposium19 Dec 2025 - Annual meeting to elect nine directors, ratify PwC, and approve executive pay, with strong governance focus.ROG
Proxy Filing2 Dec 2025 - Director elections, auditor ratification, and say-on-pay up for vote at May 2025 meeting.ROG
Proxy Filing2 Dec 2025 - Q2 2025 saw sequential sales growth, curamikⓇ impairments, and major restructuring.ROG
Q2 202516 Nov 2025